Daniel A. Yerace - 11 Feb 2026 Form 4 Insider Report for Coeptis Therapeutics Holdings, Inc. (COEP)

Reporting relationship: VP Operations, Director
Issuer ticker: COEP
Reported as of: 11 Feb 2026
Net transaction value: +$104,100
SEC form: 4
Accepted by SEC: 13 Feb 2026, 17:00:06 UTC
Prior SEC filing: 06 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Daniel A. Yerace

Key filing fact

Daniel A. Yerace filed Form 4 for Coeptis Therapeutics Holdings, Inc. (COEP) on 13 Feb 2026.

Key facts

This page summarizes Daniel A. Yerace's Form 4 filing for Coeptis Therapeutics Holdings, Inc. (COEP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Feb 2026, 17:00.

Change

Previous filing in this sequence was filed on 06 Mar 2025.
Current net transaction value: +$104,100.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001846625 Primary reporting owner

Yerace Daniel Alexander

Relationship: VP Operations, Director
Address: 105 BRADFORD RD, SUITE 420, WEXFORD
Signature: /s/ Daniel A. Yerace
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COEP transaction

Common stock

Options Exercise

Transaction value: $104,100
Shares: +10,000
Change %: +17%
Price: $10.41
Shares after: 70,531
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1

COEP transaction

Common Stock

Award

Transaction value: $0
Shares: +20,000
Change %: +40%
Price: $0.000000
Shares after: 70,531
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the weighted average exercise price of shares purchased upon exercise of stock options.

Footnote F2

Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.